Read more:
Category Archives: Neuropathology
Fibrin drives thromboinflammation and neuropathology in COVID-19 – Nature.com
Multifaceted roles of APOE in Alzheimer disease – Nature.com
Glenner, G. G. & Wong, C. W. Alzheimers disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. 120, 885890 (1984).
Article CAS PubMed Google Scholar
van Dyck, C. H. et al. Lecanemab in early Alzheimers disease. N. Engl. J. Med. 388, 921 (2023).
Article PubMed Google Scholar
Mintun, M. A. et al. Donanemab in early Alzheimers disease. N. Engl. J. Med. 384, 16911704 (2021).
Article CAS PubMed Google Scholar
Serrano-Pozo, A., Aldridge, G. M. & Zhang, Q. Four decades of research in Alzheimers disease (19752014): a bibliometric and scientometric analysis. J. Alzheimers Dis. 59, 763783 (2017).
Article PubMed PubMed Central Google Scholar
Corder, E. H. et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimers disease in late onset families. Science 261, 921923 (1993).
Article CAS PubMed Google Scholar
Farrer, L. A. et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 278, 13491356 (1997).
Article CAS PubMed Google Scholar
Corder, E. H. et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat. Genet. 7, 180184 (1994).
Article CAS PubMed Google Scholar
Reiman, E. M. et al. Exceptionally low likelihood of Alzheimers dementia in APOE2 homozygotes from a 5,000-person neuropathological study. Nat. Commun. 11, 667 (2020).
Article CAS PubMed PubMed Central Google Scholar
Mattsson, N. et al. Prevalence of the apolipoprotein E 4 allele in amyloid positive subjects across the spectrum of Alzheimers disease. Alzheimers Dement. 14, 913924 (2018).
Article PubMed Google Scholar
Belloy, M. E. et al. APOE genotype and Alzheimer disease risk across age, sex, and population ancestry. JAMA Neurol. 80, 12841294 (2023).
Article PubMed PubMed Central Google Scholar
Granot-Hershkovitz, E. et al. APOE alleles association with cognitive function differs across Hispanic/Latino groups and genetic ancestry in the study of Latinos investigation of neurocognitive aging (HCHS/SOL). Alzheimers Dement. 17, 466474 (2021).
Article CAS PubMed Google Scholar
Rajabli, F. et al. Ancestral origin of ApoE 4 Alzheimer disease risk in Puerto Rican and African American populations. PLoS Genet. 14, e1007791 (2018).
Article PubMed PubMed Central Google Scholar
Blue, E. E., Horimoto, A. R. V. R., Mukherjee, S., Wijsman, E. M. & Thornton, T. A. Local ancestry at APOE modifies Alzheimers disease risk in Caribbean Hispanics. Alzheimers Dement. 15, 15241532 (2019).
Article PubMed Google Scholar
Griswold, A. J. et al. Increased APOE 4 expression is associated with the difference in Alzheimers disease risk from diverse ancestral backgrounds. Alzheimers Dement. 17, 11791188 (2021).
Article CAS PubMed Google Scholar
Nuytemans, K. et al. Identifying differential regulatory control of APOE 4 on African versus European haplotypes as potential therapeutic targets. Alzheimers Dement. 18, 19301942 (2022).
Article CAS PubMed Google Scholar
Fortea, J. et al. APOE4 homozygosity represents a distinct genetic form of Alzheimers disease. Nat. Med. 30, 12841291 (2024).
Article CAS PubMed Google Scholar
Qian, J. et al. APOE-related risk of mild cognitive impairment and dementia for prevention trials: an analysis of four cohorts. PLoS Med. 14, e1002254 (2017).
Article PubMed PubMed Central Google Scholar
Stites, S. D. et al. Patients asking about APOE gene test results? Heres what to tell them. J. Fam. Pract. 71, E1E7 (2022).
PubMed PubMed Central Google Scholar
Wightman, D. P. et al. A genome-wide association study with 1,126,563 individuals identifies new risk loci for Alzheimers disease. Nat. Genet. 53, 12761282 (2021).
Article CAS PubMed PubMed Central Google Scholar
Bellenguez, C. et al. New insights into the genetic etiology of Alzheimers disease and related dementias. Nat. Genet. 54, 412436 (2022).
Article CAS PubMed PubMed Central Google Scholar
Huq, A. J. et al. Polygenic score modifies risk for Alzheimers disease in APOE 4 homozygotes at phenotypic extremes. Alzheimers Dement. 13, e12226 (2021).
Google Scholar
Ebenau, J. L. et al. Risk of dementia in APOE 4 carriers is mitigated by a polygenic risk score. Alzheimers Dement. 13, e12229 (2021).
Google Scholar
Erickson, C. M. et al. KLOTHO heterozygosity attenuates APOE4-related amyloid burden in preclinical AD. Neurology 92, e1878e1889 (2019).
Article CAS PubMed PubMed Central Google Scholar
Belloy, M. E. et al. Association of klotho vs heterozygosity with risk of Alzheimer disease in individuals who carry APOE4. JAMA Neurol. 77, 849862 (2020).
Article PubMed PubMed Central Google Scholar
Neitzel, J. et al. KL-VS heterozygosity is associated with lower amyloid-dependent tau accumulation and memory impairment in Alzheimers disease. Nat. Commun. 12, 3825 (2021).
Article CAS PubMed PubMed Central Google Scholar
Ali, M. et al. Leveraging large multi-center cohorts of Alzheimer disease endophenotypes to understand the role of klotho heterozygosity on disease risk. PLoS ONE 17, e0267298 (2022).
Article CAS PubMed PubMed Central Google Scholar
Huq, A. J. et al. Genetic resilience to Alzheimers disease in APOE 4 homozygotes: a systematic review. Alzheimers Dement. 15, 16121623 (2019).
Article PubMed Google Scholar
Serrano-Pozo, A. & Growdon, J. H. Is Alzheimers disease risk modifiable? J. Alzheimers Dis. 67, 795819 (2019).
Article PubMed PubMed Central Google Scholar
Jaisa-Aad, M., Muoz-Castro, C. & Serrano-Pozo, A. Update on modifiable risk factors for Alzheimers disease and related dementias. Curr. Opin. Neurol. 37, 166181 (2024).
Article PubMed Google Scholar
Kolli, A. et al. Interactions between the apolipoprotein E4 gene and modifiable risk factors for cognitive impairment: a nationally representative panel study. BMC Geriatr. 22, 938 (2022).
Article CAS PubMed PubMed Central Google Scholar
Langella, S. et al. Effect of apolipoprotein genotype and educational attainment on cognitive function in autosomal dominant Alzheimers disease. Nat. Commun. 14, 5120 (2023).
Article CAS PubMed PubMed Central Google Scholar
Park, S.-Y. et al. Modifying effects of race and ethnicity and APOE on the association of physical activity with risk of Alzheimers disease and related dementias. Alzheimers Dement. 19, 507517 (2023).
Article CAS PubMed Google Scholar
Jia, J. et al. Association between healthy lifestyle and memory decline in older adults: 10 year, population based, prospective cohort study. Br. Med. J. 380, e072691 (2023).
Article Google Scholar
Park, S.-Y. et al. Racial and ethnic differences in the population-attributable fractions of Alzheimer disease and related dementias. Neurology 102, e208116 (2024).
Article PubMed Google Scholar
Lee, M. et al. Variation in population attributable fraction of dementia associated with potentially modifiable risk factors by race and ethnicity in the US. JAMA Netw. Open 5, e2219672 (2022).
Article PubMed PubMed Central Google Scholar
Arboleda-Velasquez, J. F. et al. Resistance to autosomal dominant Alzheimers disease in an APOE3 Christchurch homozygote: a case report. Nat. Med. 25, 16801683 (2019).
Article CAS PubMed PubMed Central Google Scholar
He, K. Y. et al. Characterization of APOE Christchurch carriers in 455,306 UK Biobank participants. Mol. Neurodegener. 18, 92 (2023).
Article PubMed PubMed Central Google Scholar
Wardell, M. R., Brennan, S. O., Janus, E. D., Fraser, R. & Carrell, R. W. Apolipoprotein E2-Christchurch (136 ArgSer). New variant of human apolipoprotein E in a patient with type III hyperlipoproteinemia. J. Clin. Invest. 80, 483490 (1987).
Article CAS PubMed PubMed Central Google Scholar
Pocovi, M. et al. Incomplete dominance of type III hyperlipoproteinemia is associated with the rare apolipoprotein E2 (Arg136Ser) variant in multigenerational pedigree studies. Atherosclerosis 122, 3346 (1996).
Article CAS PubMed Google Scholar
Hernandez, I. et al. Heterozygous APOE Christchurch in familial Alzheimers disease without mutations in other Mendelian genes. Neuropathol. Appl. Neurobiol. 47, 579582 (2021).
Article CAS PubMed Google Scholar
Le Guen, Y. et al. Association of African ancestry-specific APOE missense variant r145c with risk of Alzheimer disease. JAMA 329, 551560 (2023).
Article PubMed PubMed Central Google Scholar
Medway, C. W. et al. ApoE variant p.V236E is associated with markedly reduced risk of Alzheimers disease. Mol. Neurodegener. 9, 11 (2014).
Article PubMed PubMed Central Google Scholar
Le Guen, Y. et al. Association of rare APOE missense variants V236E and R251G with risk of Alzheimer disease. JAMA Neurol. 79, 652663 (2022).
Article PubMed PubMed Central Google Scholar
Liu, C.-C. et al. APOE3-Jacksonville (V236E) variant reduces self-aggregation and risk of dementia. Sci. Transl. Med. 13, eabc9375 (2021).
Article CAS PubMed PubMed Central Google Scholar
Boyle, P. A. et al. Person-specific contribution of neuropathologies to cognitive loss in old age. Ann. Neurol. 83, 7483 (2018).
Article CAS PubMed PubMed Central Google Scholar
Bennett, D. A. et al. Amyloid mediates the association of apolipoprotein E e4 allele to cognitive function in older people. J. Neurol. Neurosurg. Psychiatry 76, 11941199 (2005).
Article CAS PubMed PubMed Central Google Scholar
Mungas, D., Tractenberg, R., Schneider, J. A., Crane, P. K. & Bennett, D. A. A 2-process model for neuropathology of Alzheimers disease. Neurobiol. Aging 35, 301308 (2014).
Article CAS PubMed Google Scholar
Serrano-Pozo, A., Qian, J., Monsell, S. E., Betensky, R. A. & Hyman, B. T. APOE2 is associated with milder clinical and pathological Alzheimer disease. Ann. Neurol. 77, 917929 (2015).
Article CAS PubMed PubMed Central Google Scholar
Goldberg, T. E., Huey, E. D. & Devanand, D. P. Association of APOE 2 genotype with Alzheimers and non-Alzheimers neurodegenerative pathologies. Nat. Commun. 11, 4727 (2020).
Article CAS PubMed PubMed Central Google Scholar
Goldberg, T. E., Huey, E. D. & Devanand, D. P. Associations of APOE 2 genotype with cerebrovascular pathology: a postmortem study of 1275 brains. J. Neurol. Neurosurg. Psychiatry https://doi.org/10.1136/jnnp-2020-323746 (2020).
Yu, L. et al. APOE and cerebral amyloid angiopathy in community-dwelling older persons. Neurobiol. Aging 36, 29462953 (2015).
Follow this link:
Multifaceted roles of APOE in Alzheimer disease - Nature.com
Senolytics show promise in combating brain aging and COVID-19 … – News-Medical.Net
In a recent study published in the journal Nature Aging, an international team of researchers observed that senolytics can alleviate physiologic brain aging and coronavirus disease 2019 (COVID-19) neuropathology.Senolytics are a class of drugs that selectively target and eliminate senescent cells, which are cells that have stopped dividing and contribute to aging and age-related diseases.
Most COVID-19 patients often experience diverse neurologic complications. Further, autopsied brain tissue transcriptomic data suggest associations between severe COVID patients' cognitive decline and brain aging signatures. While recent reports implicate senescent cells in neurodegeneration and cognitive decline in aged mice and in vivo neuropathology models, their contribution to human brain tissue aging and COVID-19 pathology in the central nervous system remains unknown.
Study: Senolytic therapy alleviates physiological human brain aging and COVID-19 neuropathology. Image Credit:Jose Luis Calvo/ Shutterstock
In the present study, researchers tested the effects of senolytics on physiological brain aging and COVID-19 neuropathology. First, they generated human brain organoids (BOs) from embryonic stem cells and physiologically aged them for eight months. Subsequently, the BOs were treated with two doses of senolytics, such as the dasatinib-quercetin (D+Q) combination, ABT-737, and navitoclax, for one month at a two-week interval.
Senolytic interventions significantly reduced senescence-associated -galactosidase (SA--gal) activity, indicating the elimination of senescent cells. This was further confirmed by significantly higher levels of lamin B1 (a nuclear marker downregulated in senescence) in treated BOs. Next, the team investigated the cell types involved in senescence phenotypes by co-immunolabeling with a senescence marker (p16).
Over three-fourths of p16-positive cells coimmunostained with astrocytes (positive for glial fibrillary acidic protein), while approximately 15% co-localized with mature neurons (positive for neuronal nuclei antigen). These two brain cell populations represented a majority (> 90%) of p16-positive cells. The team found a significant reduction in senescent astrocyte populations following treatment, with the D+Q combination being the most potent. However, the effect of senolytics in reducing senescent neurons was less apparent.
RNA sequencing revealed the upregulation of lamin B1 messenger RNA (mRNA) levels across all senolytic treatments. Additionally, 81 senescence-related mRNAs were consistently suppressed with senolytic treatments. Further, aging clock predictions were performed based on whole-transcriptome sequencing. D+Q treatment of nine-month-old organoids returned their gene expression age to levels of eight-month-old organoids.
This phenotype was not observed with other tested senolytic interventions. D+Q treatment-induced changes in gene expression correlated with mammalian signatures of pro-longevity interventions, such as rapamycin administration and caloric restriction. Next, the team estimated the prevalence of senescent cells in the autopsied frontal cortex from the brains of age-matched patients who died due to severe COVID-19 or non-neurologic and non-infectious causes.
Brains of COVID-19 decedents showed over seven-fold increase in p16-positive cells than those from non-COVID-19 controls. Next, human BOs were exposed to different viral pathogens to examine how (neurotropic) viruses contribute to aging-induced neuropathology. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection was mainly detected in neurons, microglia, and neural progenitors.
Seven SARS-CoV-2 variants were also tested, and their senescence phenotypes were ranked by SA--gal activity. Most variants significantly increased SA--gal, but the Delta variant exhibited the most potent induction. Moreover, there was a distinctive colocalization of viral spike and SA--gal in Delta-infected BOs. Besides, a statistically higher induction of senescence was evident between organoids infected for five and 10 days.
Increased senescence observed at 10 days post-infection (dpi) relative to 5 dpi suggested that SARS-CoV-2 infection may have triggered secondary senescence. Interestingly, non-infected senescent cells were enriched within 150 m of infected senescent cells, supporting the putative bystander effect of infected cells in triggering secondary senescence. Senescence was also triggered by infection of BOs with Japanese encephalitis virus (JEV), Zika virus (ZIKV), or Rocio virus (ROCV).
The researchers examined the associations of transcriptomic changes between COVID-19 patients and SARS-CoV-2-infected BOs. Among nearly 1,600 genes with differential expression between infected and non-infected BOs, there were 485 differentially expressed genes in COVID-19 patients' brain samples. Notably, known senescence and aging pathways were enriched in this common gene set.
Long-term senolytic treatment prevents selective accumulation of senescent cells in physiologically aged human BOs.af, BOs were generated and grown in vitro for 8months and subsequently exposed to two doses (one every 2weeks) of either navitoclax (2.5M), ABT-737 (10M) or D+Q (D, 10M; Q, 25M) within the following month, after which organoids (n=814) were collected for in situ analysis.a, SA--gal assay was performed on organoid sections. Each data point in the bar graph represents a single organoid analyzed. Data presented as means.d.; at least eight individual organoids were analyzed per condition; one-way analysis of variance (ANOVA) with Tukeys multiple-comparison post hoc corrections.b, Lamin B1 staining was performed on organoid sections. Each data point in the scatter plot represents the integrated intensity of each cell within organoid sections. At least eight individual organoids were analyzed per condition; one-way ANOVA with Tukeys multiple-comparison post hoc corrections.c,d, Representative images from quantifications shown ina,b, respectively. Scale bar, 0.3mm.e, Representative immunofluorescent images of regions from organoids treated with the indicated senolytics and vehicle control. Samples were individually immunolabeled with antibodies against GFAP, Sox2 and NeuN and co-stained for p16. Arrows indicate coimmunoreactivity of NeuN and p16. Scale bar, 50m.f, Bar graphs showing colocalization quantification performed on organoid sections. Data presented as means.d.; three individual organoids were analyzed per condition; one-way ANOVA with Tukeys multiple-comparison post hoc corrections. a.u., arbitrary units.
Next, the team evaluated the impact of the selective elimination of senescent cells with senolytic interventions. Senolytics significantly reduced the number of BO cells with SA--gal activity five days after SARS-CoV-2 infection. Of note, the impact of senolytics was more prominent in BOs infected with the Delta variant, and senolytics reverted Delta variant-induced lamin B1 loss and p21 upregulation.
Pretreating BOs with senolytics before infection resulted in a significant reduction of virus-induced senescence. Layer 6 corticothalamic neurons and gamma-aminobutyric acid (GABA)ergic ganglionic eminence neurons were the two populations with significantly higher incidence of senescence following infection, and senolytic interventions prevented cellular senescence in these populations.
Finally, the researchers infected K18-hACE2 mice (that express the human angiotensin-converting enzyme 2 [hACE2] under the regulation of keratin 18 [K18] promoter) with SARS-CoV-2 Delta. Senolytics with blood-brain barrier permeability, such as D+Q, navitoclax, and fisetin, were administered 24 hours post-infection, with subsequent treatments every two days. Infected mice had shortened life spans, with a median survival of five days.
However, fisetin or D+Q treatment significantly improved survival. All control animals died by 10 dpi, whereas 13% of navitoclax-, 38% of D+Q-, and 22% of fisetin-treated mice were alive at 12 dpi (experimental endpoint). Senolytics, especially D+Q, caused a profound decrease in COVID-19-related features and significantly reduced viral gene expression in mice brains.
The brains of infected mice exhibited an increase in inflammatory senescence-associated secretory phenotype (SASP) and p16 senescence markers, and (all) senolytic treatments normalized senescence and SASP gene expression of infected animals to the levels observed in non-infected brains. Delta infection also caused a loss of dopaminergic neurons in the brainstem, with a concomitant increase in astrogliosis. However, recurrent administration of senolytics partially prevented the loss of dopaminergic neurons and abrogated the onset of astrogliosis.
Taken together, the study demonstrated that senescent cells accumulate in physiologically aged human BOs, with long-term senolytic intervention(s) substantially reducing cellular senescence and inflammation. Further, D+Q treatment uniquely induced anti-aging and pro-longevity gene expression changes in BOs.
Besides, COVID-19 patients' brains exhibit rapid accumulation of cellular senescence relative to age-matched controls. Neurotropic viruses (ROCV, JEV, and ZIKV) and SARS-CoV-2 can infect BOs and induce cellular senescence, and the SARS-CoV-2 Delta variant triggers the most potent induction of senescence. Short-term senolytic interventions could reduce SARS-CoV-2 gene expression in infected BOs and prevent senescence of GABAergic and corticothalamic neurons.
Notably, senolytics ameliorated COVID-19 neuropathology in infected K18-hACE2 mice, improved their survival and clinical score, and reduced SASP, senescence, and viral gene expression. Overall, the findings highlight the vital role of cellular senescence in brain aging, COVID-19, neuropathology, and the therapeutic impact of senolytics.
Read more here:
Senolytics show promise in combating brain aging and COVID-19 ... - News-Medical.Net
Startling discovery at Great Salt Lake could lead to damaging health … – FOX 13 News Utah
SALT LAKE CITY Scientists have revealed a startling discovery made at a lake bed of the Great Salt Lake that could potentially impact the health of many Utahns.
Samples of neurotoxins gathered from a dried up lake bed were so large they shocked scientists who have been studying them for years.
The air sample had a very large signal, one of the biggest I have seen and I was very worried, said Dr. Sandra Banack, senior scientist at Brain Chemistry Labs.
Banack said the toxins in a nonhuman primate can trigger the neuropathology of Alzheimer's disease and ALS. She and her colleagues are concerned about what an exposed lake bed means when wind picks up the toxins and people breathe them in.
What we don't want to see is the increased risk of ALS among citizens here in the Wasatch Front," explained Dr. Paul Alan Cox, Executive Director of Brain Chemistry Labs.
While the study shows an increase is possible, its hard to prove.
We're talking, you know, a disease that can take 10-20 years to manifest. It's not like you can just go out and say, 'yes, that is the cause,' said Dr. James Metcalf, a senior research fellow at Brain Chemistry Labs.
The study simply tells scientists they need to do more research.
And that may then give us links as to which people are vulnerable to the action of this toxin," said Metcalf, "whether it's contributing to an increased rate of disease and ultimately protect people.
In the meantime, its the unknown risks while Wasatch Front residents keep inhaling the air that worries scientists.
As scientists, we feel very strongly that all efforts should be made to refuel the Great Salt Lake so that these water levels come up and we're not getting the dust blowing this way off the lake bottom that's dried, said Cox.
Utah political leaders and state officials tasked with helping the Great Salt Lake reacted with concern in interviews with FOX 13 News.
What can we do to protect ourselves from the already proven risks and the possibility of more found in this study?
Research on its own can't make change, explained Eliza Cowie, Policy Director at O2 Utah.
Cowie encourages people to pay attention, read up on the issues, and show up when it comes time for decisions to be made at the Utah State Capitol that impact the lake and the state's air quality.
Its really important to get people involved to take that information and produce it as a policy solution," she said. "You can't rely purely on researchers and scientists to save us. We need to kind of take the information and produce our own results.
Read this article:
Startling discovery at Great Salt Lake could lead to damaging health ... - FOX 13 News Utah
Senolytic therapies suppress long COVID in human organoids … – BioWorld Online
Infection
Researchers from the University of Queensland discovered that senolytic therapies can suppress long-COVID neuropathology and long-term disorders caused by viral infections by reducing senescent cells, thereby reducing inflammation. Published Nov. 13, 2023, in Nature, the study examined the use of human pluripotent stem cells to generate small mini human brain organoids to screen for antiaging interventions called senolytics that selectively eliminate senescent cells that accumulate with age, lead author Julio Aguado told BioWorld.
Read the rest here:
Senolytic therapies suppress long COVID in human organoids ... - BioWorld Online
Eight scientists among most-cited researchers in world – Mirage News
Eight scientists from the University of Freiburg are among the "Highly Cited Researchers" for 2023. A survey by Clarivate Analytics reveals that they are among the most-frequently cited authors worldwide in their fields of research over the past decade. With nine entries - one scientist is recognised for work in two areas - the University of Freiburg holds fifth place among German universities alongside Bonn and Dsseldorf.
The University of Freiburg's Faculty of Environment and Natural Resources is represented in the list by Prof. Dr. Jrgen Bauhus and Prof. Dr. Carsten Dormann. Bauhus' research focuses on the structure and dynamics of forests, nutrient and carbon cycles in forests and ecological interactions in forest ecosystems. Dormann researches and develops statistical ecology methods that are used for example for the analysis of ecological networks.
Dr. Bjrn Grning from the Department of Computer Science is also among the Highly Cited Researchers. Grning is an expert in bioinformatics and heads Freiburg's Galaxy team. Galaxy is an open source platform for the analysis of big data in the life sciences.
Bjrn Grning, Bertram Bengsch, Marco Prinz, Carsten Dormann, Jrg Meerpohl, Jrgen Bauhus, Lukas Schwingshackl and Ori Staszewski. Photos: SFB 1425, Freiburg University Medical Center, Christian Hanner, Jrgen Gocke, Angela Schuberth-Ziehmer.
Five researchers from the Medical Faculty among the most-cited scientists
From the Medical Faculty at the University of Freiburg, the Highly Cited Researchers include Prof. Dr. Bertram Bengsch, Prof. Dr. Jrg Meerpohl, Prof. Dr. Marco Prinz, Prof. Dr. Lukas Schwingshackl, and Dr. Ori Staszewski, who is now a neuropathology consultant at Klinikum Saarbrcken. With the direct involvement of patients, Bengsch, from the Department of Internal Medicine II, undertakes research into the adaptive immune system in chronic disease, specifically virus infections, tumour diseases and diseases brought about by the autoimmune system. Meerpohl is the head of the Institute for Evidence in Medicine at the Freiburg University Medical Center. Together with his team, he develops new ways of making scientific findings accessible to doctors more clearly, more quickly and more convincingly in review papers.
Prinz is the head of the Institute of Neuropathology at the Freiburg University Medical Center, and was recognised as a Highly Cited Researcher by Clarivate in two areas: in immunology and in the field of neural and behavioural sciences. Together with Staszewski, Prinz studies the role of the immune system in the healthy brain and its involvement in diseases such as multiple sclerosis, Alzheimer's and brain tumours. They are both researching among other things the influence of nutrition and epigenetics on the formation of the immune system in the brain. Schwingshackl, senior researcher at the Institute for Evidence in Medicine and at Cochrane Germany, analyses studies into the influence of nutrition on health and develops new methods for future dietary guidelines.
About the list
Clarivate Analytics identifies the Highly Cited Researchers from an analysis of the most-cited papers in the Web of Science literature database. The list ranks the authors of research papers that are among the top one percent in their field in the Web of Science citations index. For 2023, the survey looked at papers that were published and cited in the period from January 2012 to December 2022. In total, the list includes more than 6,800 researchers from more than 1,300 institutions across 67 countries and regions.
View the list
See the original post:
Eight scientists among most-cited researchers in world - Mirage News
UW study links past military service to Alzheimer’s disease – University of Wisconsin School of Medicine and Public Health
The brains of deceased military veterans had higher levels of two abnormal proteins considered hallmarks of Alzheimers disease, suggesting that military veterans face a greater risk for developing Alzheimers, according to a new study from the University of Wisconsin School of Medicine and Public Health.
The study was recently published in Alzheimers & Dementia: The Journal of the Alzheimers Association led byRyan Powell, PhD, MA, assistant professor of medicine, UW School of Medicine and Public Health.
Emily Greendonner 608-516-9154 egreendonner@uwhealth.org
The study found that military veterans who had donated their brains to Alzheimers disease research centers had 26% greater odds of having amyloid plaques in their brains than nonveterans and 10% greater odds of having neurofibrillary tangles made of abnormal tau proteins, according to Powell. The findings, as well as prior research showing higher frequency of Alzheimers disease risk factors among veterans, support a rationale for greater support in disease prevention and treatment interventions for this population.
To our knowledge, this is the first study to link a history of military service to Alzheimers disease neuropathology, the gold standard for diagnosing Alzheimers, said Powell, who is data science director of the UW Center for Health Disparities Research. This has important implications for the Veterans Health Administration since it indicates an urgent need to screen veterans and to target therapies to those at greatest risk.
Powell and his research collaborators looked at brain biopsy data from 597 males who died between 1986 and 2018 and donated their brains to Alzheimers disease research centers at the UW School of Medicine and Public Health and the University of California San Diego.
Genealogical archivists used genealogy databases, census and military records to determine that about 60% of the males had served in the military most likely during World War II, Korean War and Vietnam War eras. The rate of military service was consistent between those who donated brains in San Diego and in Madison, Powell said.
The group of 358 male veterans had higher levels of both amyloid plaques and tau tangles in their brains, both biomarkers of Alzheimers disease. Researching female veteran risk is a key next step but researchers were unable to conduct this analysis given the small number of them represented in the current study, Powell said.
This study is shining new light on data thats been collected over decades some donations date all the way back to the mid-1980s so the donations of these veterans are still yielding valuable new insights after all these years, he said. We identified the who and the what in this study, but we need to narrow in on the why and the when.
Veterans are exposed to many known risks for brain disorders, including chronic stress from physical and psychological pain, physical trauma including traumatic brain injuries and environmental hazards such as Agent Orange, a tactical defoliating agent used in Vietnam. In addition, veterans have higher rates of cardiovascular disease, depression and PTSD, all of which are known risk factors for dementia, Powell said.
Exposures during military service and differences in life both before and after service likely all contribute to the brain disease, he explained. Researchers hope to expand the study to other brain banks to gain a deeper understanding and include younger generations of veterans to unlock the root causes of these brain changes in veterans, he said.
We might be able to uncover other factors and learn where risks can be reduced, Powell said. And with new Alzheimers therapies coming online, theres a need for scientific-based health equity policies to get them to those who might benefit most. Its exciting that this ongoing line of research can inform policy changes that improve the health of veterans.
The study was supported by funding from the National Institutes of Health - National Institute on Aging (grants R21AG079277, R01AG070883, P30AG062715, R01AG079303, and P30AG066530).
Follow this link:
Study reveals no neuroinflammation in long COVID patients with … – News-Medical.Net
In a recent study published in JAMA Network Open, researchers examined cerebrospinal fluid (CSF) markers of neuroinflammation in individuals with post-coronavirus disease 2019 (COVID-19) condition (PCC) and neuropsychiatric symptoms.
PCC, also known as long COVID, represents a diverse group of symptoms that last for months post-acute COVID-19. Some individuals with PCC have neuropsychiatric symptoms (neuro-PCC), and the underlying mechanisms are poorly understood. CSF provides a means to evaluate neuropathology, given that it circulates the central nervous system (CNS) and serves as a window to the brain.
Research Letter: Self-Reported Neuropsychiatric PostCOVID-19 Condition and CSF Markers of Neuroinflammation. Image Credit:Donkeyworx/ Shutterstock
In the present study, researchers assessed CSF markers of neuroinflammation in people with neuro-PCC and COVID-19-nave individuals. Neuro-PCC subjects were recruited to the COVID Mind Study if they reported neuropsychiatric symptoms three months after COVID-19. Asymptomatic individuals recruited before 2020 (pre-COVID-19) served as controls.
The control group also included a COVID-19-nave participant recruited in 2022, with laboratory evidence supporting the seronegative status. Individuals with a history of immunocompromising conditions and psychiatric or neurologic illness and those taking immunosuppressive medications were excluded.
Data on COVID-19 test dates/results and vaccination were obtained from medical records and interviews. Participants provided consent for blood sampling and lumbar puncture. CSF and plasma were evaluated using a multiplex cytokine laser bead assay. Enzyme-linked immunosorbent assay (ELISA) was used to measure neopterin (microglia activation marker).
Ethnicity and race were self-reported by participants. Group comparisons for clinical and demographic data were performed using t-tests, while a two-proportion z-test was used for comparisons of race. Mann-Whitney tests were used to compare cytokine data between controls and neuro-PCC subjects, controlling for false discovery rates.
The study included 37 individuals with neuro-PCC and 22 controls. Neuro-PCC subjects tested positive for COVID-19 from March 2020 to July 2022. Most individuals with neuro-PCC were White (78.4%) and female (73%). Only four participants (11%) in the neuro-PCC group were vaccinated at the time of infection, while 89% remained non-vaccinated. However, 46% were partially or fully vaccinated at the PCC study visit.
A majority of neuro-PCC participants had acute disease when severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Alpha was the predominant variant. Cognitive impairment, brain fog, and excess fatigue were the most common PCC symptoms. The neuro-PCC group did not exhibit elevated protein levels and white blood cell counts. Moreover, the CSF-to-blood albumin ratio, which changes during the breakdown of the blood-brain barrier, was not elevated in the neuro-PCC group.
There was no evidence of intrathecal production of immunoglobulins. However, interleukin-6 (IL-6) and monocyte chemoattractant protein-1 were reduced, while tumor necrosis factor-alpha levels were elevated in the CSF of neuro-PCC subjects relative to controls, albeit not statistically significant when accounted for multiple comparisons. Besides, other chemokines and cytokines in the plasma or CSF were not significantly different. Furthermore, neopterin levels were not elevated in neuro-PCC subjects.
Taken together, the study did not find evidence of neuroinflammation and blood-brain barrier dysfunction in participants with neuro-PCC relative to control participants. The findings suggest persistent CNS immune activation does not drive neurologic long COVID. The studys limitations were the small sample size, increased rates of alcohol use and smoking, reduced rates of antidepressants among controls, and discrepancies in the race and gender of neuro-PCC subjects relative to controls.
See more here:
Study reveals no neuroinflammation in long COVID patients with ... - News-Medical.Net
Work complexity linked to better cognitive aging | National Institute … – National Institute on Aging
Higher occupational work complexity is associated with better cognition later in life, according to two recent NIA-funded studies published in Alzheimers & Dementia.
Previous research has indicated that people with complex jobs have better cognitive function as they age and a lower risk of dementia. Both of the two new studies built on these findings by exploring multiple forms of occupational complexity and cognitive outcomes. Occupational complexity with data, people, and things was classified using the Dictionary of Occupational Titles, which catalogs the type of work activities involved in different occupations. Examples of jobs with high complexity in each of these areas include a data analyst, a social worker, and a watch repairman, respectively. Education, self-reported as the highest level of education completed, was statistically accounted for as it could indicate prior cognitive abilities before entering the workforce.
In the first study, researchers from Indiana University and collaborating institutions analyzed data from 355 older adults enrolled in the Social Networks in Alzheimers Disease study. The scientists examined participants neuropsychological test results, neuroimaging data, employment history, and mild cognitive impairment (MCI) or dementia diagnoses. Most participants, age 70 on average, were retired and no longer working in their longest-held job. The researchers found complex work with people was associated with better memory, a decreased risk of MCI or dementia, and greater brain reserve the gap between brain atrophy and poor cognitive function. After accounting for education, complexity with data or things was not associated with any cognitive outcome. These findings suggest that exposure to cognitive enrichment at work, especially via social interaction, may improve cognitive outcomes and increase cognitive resilience to neuropathology. However, a limitation of the study is that the participants were not a diverse sample.
In the other study, researchers from Kaiser Permanente Northern California; University of California, San Francisco; and collaborative institutions also looked at occupational complexity and cognition, specifically in a racially and ethnically diverse sample. Researchers interviewed 1,536 participants, average age of 76 years, in the Kaiser Healthy Aging and Diverse Life Experiences study, which consists of approximately equal numbers of Asian, Black, Latino, and White older adults. Three interview cycles were completed over an average of about two and a half years to measure initial cognition and change over time.
In line with the first study, higher occupational complexity with people was associated with better performance on cognitive measures. However, contrary to that study, higher occupational complexity with data was also found to be associated with better cognitive outcomes and a slower annual rate of cognitive decline. Differences in the methodologies between the two studies may contribute to this inconsistency, but further research is needed. Of note, a greater proportion of Black and Latino participants were categorized in jobs with lowest complexity for working with data and people.
These two studies add to an increasing body of research demonstrating that intellectually stimulating activities during midlife, such as complex work environments, may be associated with better cognitive outcomes among older adults. Its important to note that the Dictionary of Occupational Titles assigns scores according to job titles and does not capture individual variability within the same title. Further research to better understand the pathways through which different types of occupational complexity affect cognition in later life could help to create work environments that promote cognitive health and health equity.
This research was supported in part by NIA grants R01AG057739, R01AG070931, P30AG010133, P30AG072976, R01AG066132, R01AG052132, and R00AG073457.
These activities relate to NIHs Alzheimers and Related Dementias Research Implementation Milestones:
References:
Coleman ME, et al. Social enrichment on the job: Complex work with people improves episodic memory, promotes brain reserve, and reduces the risk of dementia. Alzheimers & Dementia. 2023;19(6):2655-2665. doi: 10.1002/alz.13035.
Soh Y, et al. Association of primary lifetime occupational cognitive complexity and cognitive decline in a diverse cohort: Results from the KHANDLE study. Alzheimers & Dementia. 2023;19(9):3926-3935. doi: 10.1002/alz.13038.
See more here: